Endocrinology of Pregnancy — MCQs

Endocrinology of Pregnancy Indian Medical PG Practice Questions and MCQs

Question 91: Which among the following is a manifestation of LCHAD deficiency?

A. Fatty liver of pregnancy
B. Liver failure
C. HELLP syndrome
D. All of the above (Correct Answer)

Explanation: **Explanation:** **LCHAD (Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase) deficiency** is an autosomal recessive mitochondrial fatty acid oxidation disorder. The association between a fetus with LCHAD deficiency and maternal liver disease is a high-yield concept in obstetric medicine. **1. Why "All of the Above" is Correct:** When a fetus is homozygous for LCHAD deficiency, it cannot oxidize long-chain fatty acids. These unmetabolized fatty acids (3-hydroxyacyl metabolites) cross the placenta into the maternal circulation. If the mother is a carrier (heterozygous), her liver has reduced capacity to process these extra lipids. This metabolic "overload" leads to hepatotoxicity, manifesting as a spectrum of microvesicular fatty infiltration. * **A & B (AFLP and Liver Failure):** LCHAD deficiency is most strongly linked to **Acute Fatty Liver of Pregnancy (AFLP)**. AFLP is a medical emergency that rapidly progresses to **Liver Failure**, encephalopathy, and coagulopathy. * **C (HELLP Syndrome):** There is a significant clinical overlap between AFLP and **HELLP syndrome**. Studies show that approximately 20% of mothers carrying an LCHAD-deficient fetus will develop HELLP syndrome. **2. Clinical Pearls for NEET-PG:** * **The Mutation:** The most common mutation associated is **G1528C**. * **Management:** If a mother develops AFLP or HELLP, the newborn **must be screened** for LCHAD deficiency to prevent neonatal hypoglycemia, cardiomyopathy, and sudden death. * **AFLP vs. HELLP:** While both involve the liver, AFLP is characterized by significant **hypoglycemia** and **prolonged PT/APTT**, which helps differentiate it from pure HELLP syndrome. * **Definitive Treatment:** Delivery of the fetus is the only definitive treatment to stop the influx of fetal metabolites.

Question 92: What is the anti-hypertensive agent of choice in pregnancy?

A. Labetalol (Correct Answer)
B. Hydralazine
C. Methyldopa
D. Clonidine

Explanation: **Explanation:** The management of hypertension in pregnancy has evolved, and **Labetalol** is now considered the **first-line antihypertensive agent** (drug of choice) according to recent ACOG and FIGO guidelines. **1. Why Labetalol is Correct:** Labetalol is a combined **alpha and beta-adrenergic blocker**. It effectively lowers blood pressure by decreasing systemic vascular resistance while maintaining stroke volume and cardiac output. It has a rapid onset of action, a favorable safety profile, and is not associated with significant fetal growth restriction compared to pure beta-blockers like Atenolol. **2. Analysis of Incorrect Options:** * **Methyldopa (Option C):** Historically the drug of choice due to its long-term safety data. However, it is now considered a **second-line agent** because it has a slow onset of action (3–6 hours), causes significant maternal sedation/depression, and is less effective in controlling severe hypertension. * **Hydralazine (Option B):** A direct vasodilator used primarily in **acute hypertensive emergencies**. It is not used for maintenance therapy due to side effects like reflex tachycardia, fluid retention, and a lupus-like syndrome. * **Clonidine (Option D):** A centrally acting alpha-2 agonist. While safe, it is rarely used due to a high side-effect profile (rebound hypertension and sedation). **3. NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC) for Chronic/Gestational HTN:** Labetalol. * **DOC for Hypertensive Crisis in Pregnancy:** IV Labetalol or IV Hydralazine (Nifedipine is also used). * **Teratogenic Antihypertensives (Contraindicated):** ACE Inhibitors and ARBs (cause fetal renal dysgenesis and oligohydramnios) and Sodium Nitroprusside (cyanide toxicity). * **Atenolol** is avoided as it is specifically linked to **Fetal Growth Restriction (FGR)**.

Question 93: During pregnancy, at what point is the maximum urinary hCG level typically reached?

A. 30 days
B. 50 days
C. 70 days (Correct Answer)
D. 90 days

Explanation: **Explanation:** Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone secreted by the syncytiotrophoblast. Its primary role is to maintain the corpus luteum, ensuring the continued production of progesterone until the placenta takes over (the luteo-placental shift). **Why 70 days is correct:** hCG levels rise exponentially following implantation. In a normal pregnancy, the concentration doubles every 48–72 hours. The hormone reaches its **peak concentration** (both in serum and urine) between **8 to 11 weeks of gestation** (60 to 80 days). Therefore, **70 days** represents the median point of this peak window. After this peak, levels decline to a lower plateau which is maintained for the remainder of the pregnancy. **Analysis of Incorrect Options:** * **30 days:** At this stage (approx. 4 weeks), hCG is just beginning to rise significantly and is used for early pregnancy detection, but it is far from its peak. * **50 days:** While levels are high at 7 weeks, they have not yet reached the maximum physiological concentration. * **90 days:** By 12–13 weeks, hCG levels have already begun their characteristic decline from the peak. **High-Yield Clinical Pearls for NEET-PG:** * **Doubling Time:** hCG levels double every 2 days in early pregnancy. Failure to double suggests ectopic pregnancy or impending abortion. * **Subunits:** The **$\beta$-subunit** is specific to hCG (the $\alpha$-subunit is identical to LH, FSH, and TSH). * **Abnormal Peaks:** Pathologically high hCG levels (>100,000 mIU/mL) are seen in **Molar pregnancies** and **Choriocarcinoma**. * **Low Levels:** Seen in ectopic pregnancies and spontaneous abortions. * **Down Syndrome:** Maternal serum hCG is typically **elevated** in the second-trimester Quadruple screen for Down Syndrome.

Question 94: hCG is secreted by:

A. Cytotrophoblast
B. Chorionic villi
C. Syncytiotrophoblast (Correct Answer)
D. None of the above

Explanation: **Explanation:** Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone essential for maintaining the corpus luteum during early pregnancy. **1. Why Syncytiotrophoblast is correct:** The **syncytiotrophoblast** is the outer, multi-nucleated layer of the trophoblast that invades the uterine wall. It is the functional endocrine unit of the placenta. It synthesizes and secretes not only hCG but also Human Placental Lactogen (hPL) and steroid hormones (progesterone and estrogen). hCG production begins as early as the day of implantation (roughly 8–9 days after fertilization) and can be detected in maternal blood shortly thereafter. **2. Why other options are incorrect:** * **Cytotrophoblast:** This is the inner, single-cell layer of the trophoblast (the "stem cells" of the placenta). While cytotrophoblasts produce Releasing Hormones (like GnRH), they do not directly secrete hCG. They proliferate and fuse to form the syncytiotrophoblast. * **Chorionic villi:** This is an anatomical term describing the finger-like projections of the fetal tissue. While the syncytiotrophoblast covers these villi, the term "chorionic villi" is too broad as it includes the mesoderm, fetal capillaries, and cytotrophoblasts. The specific secretory source is the syncytial layer. **3. NEET-PG High-Yield Clinical Pearls:** * **Structure:** hCG is a heterodimer. The **α-subunit** is identical to LH, FSH, and TSH. The **β-subunit** is unique, which is why pregnancy tests specifically measure **β-hCG**. * **Doubling Time:** In early normal pregnancy, β-hCG levels double every **48–72 hours**. * **Peak Levels:** hCG levels reach their peak at **8–10 weeks** of gestation (approx. 100,000 mIU/mL) and then decline to a lower plateau for the remainder of the pregnancy. * **Clinical Marker:** Pathologically high levels are seen in **Molar pregnancy** and **Down Syndrome** (triple/quadruple screen), while low levels for gestational age may indicate an **ectopic pregnancy** or impending miscarriage.

Question 95: Which of the following is NOT a feature of Stein-Leventhal syndrome?

A. Increased androgens
B. Increased or normal oestrogen
C. Galactorrhoea (Correct Answer)
D. Increased LH

Explanation: **Explanation:** **Stein-Leventhal Syndrome**, now more commonly known as **Polycystic Ovary Syndrome (PCOS)**, is a complex endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. **Why Galactorrhoea is the correct answer:** Galactorrhoea (milky nipple discharge) is typically associated with **Hyperprolactinemia**, not PCOS. While a small percentage of PCOS patients may show mildly elevated prolactin levels, galactorrhoea is not a defining clinical feature of the syndrome. Its presence should prompt a clinician to investigate other pathologies, such as a pituitary adenoma (prolactinoma). **Analysis of Incorrect Options:** * **Increased Androgens:** This is a hallmark of PCOS. Excess LH stimulates the ovarian theca cells to produce high levels of testosterone and androstenedione, leading to hirsutism and acne. * **Increased or Normal Oestrogen:** In PCOS, there is no "estrogen deficiency." Instead, there is "unopposed estrogen" due to the peripheral conversion of androgens into estrone (E1) in adipose tissue. The lack of progesterone (due to anovulation) creates a state of chronic estrogen stimulation. * **Increased LH:** A classic biochemical finding is an **elevated LH:FSH ratio (usually >2:1 or 3:1)**. High pulse frequency of GnRH favors LH secretion over FSH, leading to follicular arrest. **High-Yield Clinical Pearls for NEET-PG:** * **Rotterdam Criteria:** Diagnosis requires 2 out of 3: (1) Clinical/biochemical hyperandrogenism, (2) Oligo/anovulation, (3) Polycystic ovaries on ultrasound (≥12 follicles or volume >10ml). * **Metabolic Link:** Insulin resistance and hyperinsulinemia are central to the pathogenesis, increasing the risk of Type 2 Diabetes and Endometrial Hyperplasia/Carcinoma. * **Drug of Choice:** **Clomiphene Citrate** was traditionally the first-line for ovulation induction, but **Letrozole** (Aromatase inhibitor) is now considered the gold standard.

Question 96: A 17-year-old girl presents with amenorrhea, atrophied breasts, and a hypoplastic uterus. What is the most likely diagnosis?

A. Turner's syndrome (Correct Answer)
B. Gonadal dysgenesis
C. Androgen insensitivity syndrome
D. Klinefelter's syndrome

Explanation: **Explanation:** The clinical presentation of **primary amenorrhea**, **atrophied (underdeveloped) breasts**, and a **hypoplastic uterus** points toward **Hypergonadotropic Hypogonadism**. In this condition, the lack of estrogen leads to a failure of secondary sexual characteristic development (Tanner Stage 1 breasts) and an infantile/hypoplastic uterus. **1. Why Turner’s Syndrome (45, XO) is correct:** Turner’s syndrome is the most common cause of primary amenorrhea. The absence of the second X chromosome leads to accelerated oocyte atresia, resulting in **"streak gonads."** Because the ovaries fail to produce estrogen, the breasts remain atrophied and the uterus remains hypoplastic. The presence of a uterus (Müllerian structures) is key, as it confirms the absence of Anti-Müllerian Hormone (AMH). **2. Why other options are incorrect:** * **Gonadal Dysgenesis:** While Turner’s is a form of gonadal dysgenesis, "Turner’s Syndrome" is the more specific clinical diagnosis for a 17-year-old presenting with this classic phenotype. Pure gonadal dysgenesis (e.g., Swyer Syndrome) presents with a normal stature, whereas Turner’s typically involves short stature and other stigmata. * **Androgen Insensitivity Syndrome (AIS):** In AIS (46, XY), patients have **well-developed breasts** (due to peripheral conversion of testosterone to estrogen) but an **absent uterus** (due to AMH production by testes). * **Klinefelter’s Syndrome (47, XXY):** This affects phenotypic **males**. It presents with small testes, infertility, and gynecomastia, not amenorrhea. **High-Yield NEET-PG Pearls:** * **Most common karyotype in Turner’s:** 45, XO. * **Hormonal Profile:** High FSH/LH (Hypergonadotropic) and Low Estrogen (Hypogonadism). * **Associated findings:** Short stature, webbed neck (pterygium colli), shield chest, and coarctation of the aorta. * **Gold Standard Diagnosis:** Karyotyping.

Question 97: Schwangershaft protein is the other name of which of the following substances?

A. hCG
B. Papp-1
C. Pregnancy specific beta1 glycoprotein (Correct Answer)
D. Activin

Explanation: **Explanation:** **Schwangerschaftsprotein 1 (SP1)**, also known as **Pregnancy-specific beta-1 glycoprotein (PSβG)**, is a major oncofetal protein produced by the syncytiotrophoblast. The name is derived from the German word *"Schwangerschaft,"* meaning pregnancy. It is detectable in maternal serum shortly after implantation (around day 7 post-fertilization) and its levels rise steadily until term, reflecting placental growth and function. **Analysis of Options:** * **Option C (Correct):** SP1 is the classic biochemical name for Pregnancy-specific beta-1 glycoprotein. It is used clinically as a marker for placental function and in the monitoring of gestational trophoblastic diseases (GTD). * **Option A (hCG):** Human Chorionic Gonadotropin is a glycoprotein hormone, not SP1. While it is the earliest marker of pregnancy, it is structurally distinct (alpha and beta subunits). * **Option B (PAPP-A):** Pregnancy-associated plasma protein A is a metalloproteinase. It is a crucial screening marker for Down syndrome in the first trimester, but it is not synonymous with Schwangerschaft protein. * **Option D (Activin):** Activins are proteins involved in TGF-beta signaling and regulate FSH secretion; they are not specific to the "Schwangerschaft" nomenclature. **High-Yield Clinical Pearls for NEET-PG:** * **Production Site:** Syncytiotrophoblast (similar to hCG and hPL). * **Clinical Utility:** Low levels of SP1 are associated with **IUGR** (Intrauterine Growth Restriction) and threatened abortion. * **Tumor Marker:** SP1 can be used alongside hCG to monitor **Choriocarcinoma** and Hydatidiform mole; a persistent rise after evacuation suggests persistent trophoblastic disease. * **Doubling Time:** Like hCG, SP1 levels double approximately every 2–3 days in early pregnancy.

Question 98: Regarding hemodynamic changes in pregnancy, which of the following is NOT true?

A. Hemodynamic changes start taking place after 12 weeks of gestation. (Correct Answer)
B. Venocaval compression begins at about 16 weeks of gestation.
C. There is a mid-trimester fall in blood pressure.
D. A systolic murmur may occur normally.

Explanation: ### Explanation **1. Why Option A is the Correct Answer (The False Statement):** Hemodynamic changes in pregnancy do not wait until the second trimester; they begin **very early**, typically by the **5th to 6th week** of gestation. Cardiac output increases by as much as 10–15% by the end of the first trimester. The early onset is driven by the metabolic demands of the fetus and the vasodilatory effects of progesterone and nitric oxide. Therefore, stating that changes start after 12 weeks is physiologically incorrect. **2. Analysis of Incorrect Options (True Statements):** * **Option B:** Venocaval compression (Supine Hypotension Syndrome) typically begins around **16–20 weeks** as the gravid uterus becomes heavy enough to compress the inferior vena cava when the mother is in a supine position. * **Option C:** There is a characteristic **mid-trimester fall in blood pressure** (reaching its nadir at 20–24 weeks). This is due to a significant decrease in Systemic Vascular Resistance (SVR) caused by the low-resistance uteroplacental circulation and hormonal vasodilation. * **Option D:** A **systolic murmur** (Grade I or II) is considered physiological in over 90% of pregnant women. It is a "flow murmur" caused by increased blood volume and decreased blood viscosity. (Note: Diastolic murmurs are always pathological). **3. NEET-PG High-Yield Pearls:** * **Cardiac Output (CO):** Increases by 40–50%. The maximum increase occurs by **20–24 weeks**. * **Blood Volume:** Increases by 40–50%, but Plasma Volume increases more than RBC mass, leading to **Physiological Anemia**. * **Heart Sounds:** S1 becomes louder; there is a functional systolic murmur; S3 may be heard. * **Positioning:** Cardiac output is highest in the **left lateral position** and lowest in the supine position during late pregnancy.

Question 99: A pregnant female at 35 weeks of gestation is diagnosed with SLE. Which of the following drugs can be used to treat SLE during pregnancy, EXCEPT:

A. Corticosteroids
B. Azathioprine
C. Methotrexate (Correct Answer)
D. Hydroxychloroquine

Explanation: **Explanation:** The management of Systemic Lupus Erythematosus (SLE) during pregnancy requires balancing maternal disease control with fetal safety. The correct answer is **Methotrexate**, as it is strictly contraindicated in pregnancy. **1. Why Methotrexate is the Correct Answer:** Methotrexate is a folic acid antagonist that inhibits dihydrofolate reductase. It is a potent **teratogen** (FDA Category X). Exposure during the first trimester leads to "Methotrexate-induced fetopathy," characterized by cranial anomalies (craniosynostosis), limb defects, and growth restriction. It is also used as a medical management for ectopic pregnancy due to its ability to inhibit rapidly dividing trophoblastic cells. **2. Why the other options are incorrect:** * **Corticosteroids:** Prednisolone and Methylprednisolone are the mainstays for SLE flares. They are metabolized by placental 11β-hydroxysteroid dehydrogenase, meaning very little active drug reaches the fetus. (Note: Dexamethasone/Betamethasone *do* cross the placenta and are used for fetal lung maturity). * **Azathioprine:** Considered the steroid-sparing agent of choice in pregnancy. The fetal liver lacks the enzyme (thiopurine methyltransferase) to convert it into its active toxic metabolites, protecting the fetus. * **Hydroxychloroquine (HCQ):** Highly recommended to continue throughout pregnancy. It prevents lupus flares and reduces the risk of neonatal congenital heart block. **High-Yield Clinical Pearls for NEET-PG:** * **Safe in Pregnancy:** HCQ, Steroids, Azathioprine, Cyclosporine. * **Teratogenic (Avoid):** Methotrexate, Mycophenolate Mofetil (causes "faciodigital" malformations), Cyclophosphamide (except in life-threatening scenarios in 2nd/3rd trimester). * **Neonatal Lupus:** Associated with maternal **Anti-Ro (SSA)** and **Anti-La (SSB)** antibodies; the most serious complication is permanent congenital third-degree heart block.

Question 100: What is the screening test for gestational diabetes?

A. Oral glucose tolerance test
B. Fasting blood sugar
C. Glycosylated hemoglobin measurement
D. Random glucose challenge (Correct Answer)

Explanation: In the context of screening for Gestational Diabetes Mellitus (GDM), the **Random Glucose Challenge Test (GCT)**—specifically the **50g Glucose Challenge Test**—is the gold standard screening tool used between 24 and 28 weeks of gestation. ### Why Option D is Correct The 50g GCT is a **screening test**, meaning it is designed to be highly sensitive and easy to administer. It does not require the patient to be fasting. A 50g oral glucose load is given, and plasma glucose is measured after one hour. If the value is $\geq$ 140 mg/dL (or 130 mg/dL in some protocols), it is considered positive, necessitating a follow-up diagnostic test. ### Why Other Options are Incorrect * **A. Oral Glucose Tolerance Test (OGTT):** This is a **diagnostic test**, not a screening test (in the traditional two-step approach). It involves a 75g or 100g load and requires fasting. * **B. Fasting Blood Sugar (FBS):** While used in the IADPSG/DIPSI criteria, FBS alone lacks the sensitivity to detect GDM triggered by the insulin resistance of pregnancy (mediated by Human Placental Lactogen). * **C. Glycosylated Hemoglobin (HbA1c):** HbA1c reflects glucose control over the past 3 months. It is useful for diagnosing pre-gestational diabetes but is insensitive for GDM due to the rapid physiological changes in pregnancy and increased red cell turnover. ### NEET-PG High-Yield Pearls * **DIPSI Guidelines (Indian Context):** India often follows the "Single Step" DIPSI criteria where a **75g glucose load** is given regardless of fasting status. If 2-hour plasma glucose is $\geq$ 140 mg/dL, GDM is diagnosed. * **Timing:** Screening is typically done at **24–28 weeks** because placental hormones (HPL, Cortisol, Progesterone) reach peak levels, increasing insulin resistance. * **Best Initial Test:** If a patient has high-risk factors (obesity, prior GDM), screening should be done at the **first prenatal visit**.

Practice by Chapter

Endocrine Changes in Normal Pregnancy

Practice Questions

Thyroid Disorders in Pregnancy

Practice Questions

Diabetes in Pregnancy

Practice Questions

Adrenal Disorders in Pregnancy

Practice Questions

Pituitary Disorders in Pregnancy

Practice Questions

Hyperemesis Gravidarum

Practice Questions

Hormonal Regulation of Labor

Practice Questions

Pharmacokinetics of Hormones in Pregnancy

Practice Questions

Fetal Endocrine Development

Practice Questions

Placental Hormones

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free